Evidence map›Paper›PMID 38567176›Full record

ArticleJournal of pediatric genetics2024

Impact of Deletion on Angelman Syndrome Phenotype Variability: Phenotype-Genotype Correlation in 97 Patients with Motor Developmental Delay.

Hanae Daha Belghiti, Meriame Abbassi, Hanane Sayel, Mohamed Ahakoud, Badr Eddine El Makhzen, Norman Lee, Silvia Russo, Sana Chaouki, Laila Bouguenouch

Open access · greenAbstract read
In one paragraph

Article in Journal of pediatric genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Hanae Daha BelghitiMedical Center of Biomedical and Translational Research, Hassan II University Hospital, Fez, Morocco.ORCID 0000-0003-4969-8529
Meriame AbbassiUnit of Medical Genetics and Oncogenetics, University Hospital Hassan II, Fez, Morocco.
Hanane SayelUnit of Medical Genetics and Oncogenetics, University Hospital Hassan II, Fez, Morocco.
Mohamed AhakoudUnit of Medical Genetics and Oncogenetics, University Hospital Hassan II, Fez, Morocco.
Badr Eddine El MakhzenUnit of Medical Genetics and Oncogenetics, University Hospital Hassan II, Fez, Morocco.
Norman LeeDepartment of Pharmacology and Physiology, The George Washington University School of Medicine and Health Sciences, Washington, United States.
Silvia RussoIstituto Auxologico Italiano Istituto di Ricovero e Cura a Carattere Scientifico, Cytogenetics and Molecular Genetics Laboratory, Milano, Lombardia, Italy.
Sana ChaoukiDepartment of Neuropediatrics, Hospital University Hassan II, Fez, Morocco.
Laila BouguenouchUnit of Medical Genetics and Oncogenetics, University Hospital Hassan II, Fez, Morocco.
Centre Hospitalier Universitaire Hassan II · MAGeorge Washington University · USIRCCS Istituto Auxologico Italiano · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angelman syndrome (AS) is a rare neurodevelopmental disorder due to genetic defects involving chromosome 15, known by intellectual disability, cognitive and behavioral disorders, ataxia, delayed motor development, and seizures. This study highlights the clinical spectrum and molecular research to establish the genotype-phenotype correlation in the pediatric Moroccan population. Methylation-specific-polymerase chain reaction (MS-PCR) is a primordial technique not only to identify the genetic mechanism of AS but also to characterize the different molecular classes induced in the appearance of the clinical symptoms. Patients with positive methylation profile were additionally studied by fluorescent in situ hybridization. Sequencing analysis of the UBE3A gene was performed for patients with negative MS-PCR. We used Fisher's test to assess differences in the distribution of features frequencies among the deletional and the nondeletional group. Statistical analysis was performed using R project. We identified from 97 patients diagnosed with AS, 14 (2.06%) had a classical AS phenotype, while 70 (84.5%) patients displayed a subset of consistent and frequent criteria. Development delay was shown severe in 63% and moderate in 37%. Nineteen out of 97 of them had MS-PCR positive in which 17 (89.47%) had 15q11-q13 deletion. Deletion patients presented a higher incidence of epileptic seizures (

Indexed as

Angelman syndromedeletionMethylation-specific-polymerase chain reactionUBE3A

Identifiers

PMID38567176
PMCPMC10984711
OpenAlexW4293870266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.